|
USRE39042E
|
|
Etherlipid-containing multiple lipid liposomes
|
|
EP1268414A1
|
|
Ceramide derivatives and method of use
|
|
AU1776801A
|
|
Modular targeted liposomal delivery system
|
|
CA2376859A1
|
|
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
|
PL351487A1
|
|
Encapsulation of bioactive complexes in liposomes
|
|
AU4190699A
|
|
Novel particulate formulations
|
|
NZ335189A
|
|
Use of taxane hydrophobic derivatives for the treatment of cancer
|
|
US6107332A
|
|
Hydrolysis-promoting hydrophobic taxane derivatives
|
|
US6007839A
|
|
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
|
US5965159A
|
|
Etherlipid-containing multiple lipid liposomes
|
|
US5942246A
|
|
Etherlipid containing multiple lipid liposomes
|
|
NZ336539A
|
|
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
|
CA2276269A1
|
|
N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
|
|
US5932242A
|
|
Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
|
|
US6153736A
|
|
Modified ether glyceroglycolipids
|
|
PL325477A1
|
|
Hydrolysis facilitating hydrophobous derivatives of taxane
|
|
JPH0940550A
|
|
Method for catching compound into sterol vesicle
|
|
US6015716A
|
|
Detection of endotoxin levels in liposomes, lipid bilayers and lipid complexes
|
|
US5716526A
|
|
Method of separating materials from liposomes or lipid complexes
|
|
WO9611670A1
|
|
Ether lipid liposomes and their therapeutic use
|
